CN106176744A - Valsartan amlodipine capsule application in the medicine of preparation treatment apoplexy - Google Patents

Valsartan amlodipine capsule application in the medicine of preparation treatment apoplexy Download PDF

Info

Publication number
CN106176744A
CN106176744A CN201610545636.3A CN201610545636A CN106176744A CN 106176744 A CN106176744 A CN 106176744A CN 201610545636 A CN201610545636 A CN 201610545636A CN 106176744 A CN106176744 A CN 106176744A
Authority
CN
China
Prior art keywords
valsartan
medicine
amlodipine
preparation treatment
apoplexy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201610545636.3A
Other languages
Chinese (zh)
Inventor
张志芬
王兆龙
周云中
吴迪
任金燕
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
JINGHUA PHARMACEUTICAL GROUP Co Ltd
Original Assignee
JINGHUA PHARMACEUTICAL GROUP Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by JINGHUA PHARMACEUTICAL GROUP Co Ltd filed Critical JINGHUA PHARMACEUTICAL GROUP Co Ltd
Priority to CN201610545636.3A priority Critical patent/CN106176744A/en
Publication of CN106176744A publication Critical patent/CN106176744A/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients

Abstract

The invention discloses the application in the medicine of preparation treatment apoplexy of a kind of valsartan amlodipine capsule, described valsartan amlodipine capsule is made up of following component: valsartan 160mg, amlodipine 5mg.The present invention treats apoplexy and has obvious curative effects.

Description

Valsartan amlodipine capsule application in the medicine of preparation treatment apoplexy
Technical field
The present invention relates to the purposes of a kind of medicine.
Background technology
Existing valsartan, amlodipine are mainly used in treating hypertension, do not have further indication.Existing treatment The medicine of apoplexy is a lot, but all has certain limitation.
Summary of the invention
It is an object of the invention to provide a kind of valsartan amlodipine capsule in the medicine of preparation treatment apoplexy Application.
The technical solution of the present invention is:
The application in the medicine of preparation treatment apoplexy of a kind of valsartan amlodipine capsule, is characterized in that: described valsartan Amlodipine capsule is made up of following component:
Valsartan 160mg, amlodipine 5mg.
The present invention treats apoplexy and has obvious curative effects.
Model case:
1, Zhang Mounan, man, 69 years old, suffer from apoplexy, through one week routine medication, curative effect was the most notable；After use the present invention, every day instead Once (each valsartan 160mg, amlodipine 5mg), after one week, manifest symptom is obviously improved, progressively rehabilitation.
2, Chen, man, 51 years old, suffers from apoplexy, with the present invention, once a day (each valsartan 160mg, amlodipine 5mg), after one week, manifest symptom is obviously improved, progressively rehabilitation.
Below in conjunction with embodiment, the invention will be further described.
Detailed description of the invention
The application in the medicine of preparation treatment apoplexy of a kind of valsartan amlodipine capsule, described valsartan ammonia chlorine ground Flat capsule is made up of following component:
Valsartan 160mg, amlodipine 5mg.
Instructions about how to take medicine: once a day, each valsartan 160mg, amlodipine 5mg.Take in the morning.

Claims (1)

1. a valsartan amlodipine capsule application in the medicine of preparation treatment apoplexy, is characterized in that: described figured silk fabrics is husky Smooth amlodipine capsule is made up of following component:
Valsartan 160mg, amlodipine 5mg.
CN201610545636.3A 2016-07-13 2016-07-13 Valsartan amlodipine capsule application in the medicine of preparation treatment apoplexy Pending CN106176744A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201610545636.3A CN106176744A (en) 2016-07-13 2016-07-13 Valsartan amlodipine capsule application in the medicine of preparation treatment apoplexy

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201610545636.3A CN106176744A (en) 2016-07-13 2016-07-13 Valsartan amlodipine capsule application in the medicine of preparation treatment apoplexy

Publications (1)

Publication Number Publication Date
CN106176744A true CN106176744A (en) 2016-12-07

Family

ID=57477417

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201610545636.3A Pending CN106176744A (en) 2016-07-13 2016-07-13 Valsartan amlodipine capsule application in the medicine of preparation treatment apoplexy

Country Status (1)

Country Link
CN (1) CN106176744A (en)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101237859A (en) * 2005-08-17 2008-08-06 诺瓦提斯公司 Solid dosage forms of valsartan and amlo dipine and method of making the same
CN101507715A (en) * 2009-03-17 2009-08-19 严洁 Solid preparation of angiotensin receptor inhibitor and amlodipine and new preparation method thereof
CN102028686A (en) * 2010-11-29 2011-04-27 林海平 Valsartan amlodipine capsule and preparation method thereof

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101237859A (en) * 2005-08-17 2008-08-06 诺瓦提斯公司 Solid dosage forms of valsartan and amlo dipine and method of making the same
CN101507715A (en) * 2009-03-17 2009-08-19 严洁 Solid preparation of angiotensin receptor inhibitor and amlodipine and new preparation method thereof
CN102028686A (en) * 2010-11-29 2011-04-27 林海平 Valsartan amlodipine capsule and preparation method thereof

Similar Documents

Publication Publication Date Title
PH12015502539A1 (en) Cenicriviroc compositions and methods of making and using the same
PH12017501222A1 (en) Glucagon derivatives with improved stability
CN106109582A (en) A kind of Chinese medicine for treating rhinitis
PH12016501965A1 (en) S1p modulator immediate release dosage regimen
SG10201900559VA (en) Treatment and prevention of the common cold using povidone-iodine
CN106176744A (en) Valsartan amlodipine capsule application in the medicine of preparation treatment apoplexy
CN103800421A (en) Traditional Chinese medicine pumpkin-radix trichosanthis powder for treating diabetes
MX2015012666A (en) Complex preparation including valsartan and rosuvastatin calcium and manufacturing method therefor.
Mohanty et al. Incomplete and improper post exposure treatment leading to rabies: A case study
CN105983065A (en) Traditional Chinese medicine composition for treating insomnia
Furuta Drug allergy and bronchial asthma: 2 case reports
Lin Hypertension, diarrhoea and hand-foot syndrome: 4 case reports
CN103768178A (en) Traditional Chinese medicine pill for treating anaemia
CN103721013A (en) Traditional Chinese medicine composition used for treating herpes simplex keratitis
CN106176760A (en) Diovan compound preparation application in the medicine of preparation treatment severe hypertension
CN103800778A (en) Traditional Chinese medicine compounded gecko powder for treating impotence
CN106798773A (en) A kind of Chinese medicine for treating urinary tract infections
Xian-li et al. Clinical observation of Compound Kushen lotion plus itraconazol capsule in the treatment of malassezia folliculitis
Gumbinger et al. Breaking bad news to patients
CN103301269A (en) Traditional Chinese medicine pharbitis seed powder for treating epilepsy
CN108201607A (en) A kind of Chinese medicine composition for treating apoplexy hemiplegia and preparation method thereof
CN105560392A (en) Traditional Chinese medicine decoction for treating difficult urination
CN106727749A (en) Agent disease lamb's-quarters ball in a kind of Chinese medicine for treating leucoderma
CN106798798A (en) A kind of Chinese medicine for treating bone tuberculosis
CN104546919A (en) Traditional Chinese medicinal mantis egg-case powder for treating syphilis

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20161207